Furthermore, WHO grade 1 or 2 meningiomas with a heterozygous CDKN2A/B deletion were compared WHO grade 2 or 3 meningiomas with a CDKN2A/B wild-type status (see Fig. 5b). This evidence concerns the gene CDKN2A and meningioma.